Zobrazeno 1 - 10
of 191
pro vyhledávání: '"Sarah J. Lord"'
Autor:
Doah Cho, Sarah J. Lord, Robyn Ward, Maarten IJzerman, Andrew Mitchell, David M. Thomas, Saskia Cheyne, Andrew Martin, Rachael L. Morton, John Simes, Chee Khoon Lee
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Advances in targeted therapy development and tumor sequencing technology are reclassifying cancers into smaller biomarker-defined diseases. Randomized controlled trials (RCTs) are often impractical in rare diseases, leading to calls for s
Externí odkaz:
https://doaj.org/article/01054442bb48485e8ed565d3f77224e0
Autor:
Benjamin Daniels, Belinda E. Kiely, Monica Tang, Nehmat Houssami, Sarah J. Lord, Sallie-Anne Pearson
Publikováno v:
Breast, Vol 58, Iss , Pp 106-112 (2021)
Purpose: We aim to describe the treatment patterns and overall survival (OS) outcomes in patients receiving trastuzumab emtansine (T-DM1) for HER2-positive metastatic breast cancer (HER2+MBC) in routine clinical care. Methods: Retrospective, whole-of
Externí odkaz:
https://doaj.org/article/5d2027a064364a368a3ffcc04de90f34
Autor:
Doah Cho, Sarah J. Lord, John Simes, Wendy Cooper, Michael Friedlander, Susie Bae, Chee Khoon Lee
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: Next-generation sequencing is used to increase targeted treatment opportunities, particularly for patients who have exhausted standard options. Where randomized controlled trial evidence for a targeted therapy is available for molecular a
Externí odkaz:
https://doaj.org/article/7fa3741e3c5c428882709ca493e1fcd4
Autor:
Ziad T. A. Al-Rubaie, H. Malcolm Hudson, Gregory Jenkins, Imad Mahmoud, Joel G. Ray, Lisa M. Askie, Sarah J. Lord
Publikováno v:
BMC Pregnancy and Childbirth, Vol 20, Iss 1, Pp 1-14 (2020)
Abstract Background Guidelines recommend identifying in early pregnancy women at elevated risk of pre-eclampsia. The aim of this study was to develop and validate a pre-eclampsia risk prediction model for nulliparous women attending routine antenatal
Externí odkaz:
https://doaj.org/article/db83ac29a9d24439a56968986cbf46d1
Autor:
Katrin M. Sjoquist, Sarah J. Lord, Michael L. Friedlander, Robert John Simes, Ian C. Marschner, Chee Khoon Lee
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 10 (2018)
Background: Progression-free survival (PFS) has been adopted as the primary endpoint in many randomized controlled trials, and can be determined much earlier than overall survival (OS). We investigated whether PFS is a good surrogate endpoint for OS
Externí odkaz:
https://doaj.org/article/e28c03ad8e674c4984293aaf73ce8a24
Autor:
Jannette M. Dufour, Sarah J. Lord, Tatsuya Kin, Gina R. Rayat, Doreen E. Dixon, R. Chris Bleackley, Gregory S. Korbutt, Ray V. Rajotte
Publikováno v:
Cell Transplantation, Vol 16 (2007)
Sertoli cells (SC) protect islet allografts from immune destruction in diabetic rodents. In this study, we examined the difference between successful and rejected islet/SC cografts in order to further improve this procedure for optimal extension of i
Externí odkaz:
https://doaj.org/article/cea3cf4bf4154abe957e60494bfd0bed
Publikováno v:
BMJ Open, Vol 12, Iss 7 (2022)
Objectives Cancer is increasingly classified according to biomarkers that drive tumour growth and therapies developed to target them. In rare biomarker-defined cancers, randomised controlled trials to adequately assess targeted therapies may be infea
Externí odkaz:
https://doaj.org/article/fb8e0d11adc14493985bdedd16769a0f
Autor:
Sandy Simon, Katherine E. Francis, Janene E. Dalrymple, Val Gebski, Sarah J. Lord, Michael Friedlander, Chee Khoon Lee
Publikováno v:
European Journal of Cancer. 170:169-178
Maintenance treatment is standard of care for front-line (FL) and platinum-sensitive recurrent ovarian cancer (PSROC) following response to chemotherapy. Adverse events (AEs) on maintenance therapies are common and usually attributable to investigati
Autor:
Rachel Woodford, Deborah Zhou, Sarah J Lord, Ian Marschner, Wendy A Cooper, Craig R Lewis, Thomas John, James Chih-Hsin Yang, Chee Khoon Lee
Publikováno v:
Future Oncology. 18:1793-1799
Background: In metastatic non-small-cell lung cancer (mNSCLC), PD-L1 expression is associated with benefit from immune checkpoint inhibitor (ICI) therapy. However, the significance of PD-L1 expression in chemotherapy-treated patients is uncertain. Me
Autor:
Alison Smith, Graham R D Jones, Katy J.L. Bell, Patrick M.M. Bossuyt, Sverre Sandberg, Ferruccio Ceriotti, Tze Ping Loh, Sarah J. Lord, Andrea R. Horvath
Publikováno v:
Clinica Chimica Acta
Analytical performance specifications (APS) for measurands describe the minimum analytical quality requirements for their measurement. These APS are used to monitor and contain the systematic (trueness/ bias) and random errors (precision/ imprecision